Reported about 6 hours ago
Eli Lilly & Co. and Novo Nordisk A/S have announced a deal with the Trump administration to lower prices for their weight-loss drugs in exchange for tariff relief and better access for Medicare patients. Starting next year, certain Medicare and Medicaid patients with obesity will be able to access drugs like Zepbound and Wegovy at reduced monthly prices. This agreement is being hailed as a significant advancement in U.S. healthcare policy, aimed at making essential medications more affordable for patients.
Source: YAHOO